Logo

MorphoSys' Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA's Approval as 2L Treatment for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Share this

MorphoSys' Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA's Approval as 2L Treatment for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Shots:

  • The approval is based on P-II L-MIND study assessing Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL
  • Results: ORR (55%); CR (37%); PR (18%); mDOR (21.7mos.). Additionally- the US FDA has granted BT designation for the combination therapy for r/r DLBCL
  • Monjuvi is a humanized Fc-modified cytolytic CD19 targeting mAb- has been approved under US FDA’s accelerated approval- and is expected to be commercially available in the US. MorphoSys and Incyte will co-commercialize Monjuvi in the US & has exclusive commercialization rights outside the territory

­ Ref: MorphoSys | Image: StraitTimes

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions